AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminus of human growth hormone (amino acids 176-191). It was originally developed as an anti-obesity drug by Monash University, with the goal of isolating the fat-metabolizing effects of GH while eliminating its anabolic and insulin-resistance-inducing properties.
Selective Lipolysis
Full growth hormone exerts its fat-burning effects by stimulating lipolysis in adipocytes — the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 replicates this specific mechanism by mimicking the region of the GH molecule responsible for lipolytic activity, without activating the IGF-1 axis or causing insulin resistance.
Body Composition Applications for Athletes
For athletes focused on body composition — particularly those competing in weight-class sports or sports where power-to-weight ratio is critical — AOD-9604 offers a targeted approach to reducing body fat without the risks associated with full GH administration. It is particularly effective at targeting visceral and subcutaneous abdominal fat.
Regulatory Status
AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA in 2014, making it one of the few peptides with a formal regulatory designation. However, it is not currently FDA-approved as a pharmaceutical drug and is available only as a compounded preparation through licensed compounding pharmacies.